Nancy A. Johnson

Array ( [id] => 3682898 [patent_doc_number] => 05662904 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-09-02 [patent_title] => 'Anti-scarring compositions comprising growth factor neutralizing antibodies' [patent_app_type] => 1 [patent_app_number] => 8/122508 [patent_app_country] => US [patent_app_date] => 1993-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5938 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/662/05662904.pdf [firstpage_image] =>[orig_patent_app_number] => 122508 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3763811 [patent_doc_number] => 05844091 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-12-01 [patent_title] => 'Antibody having binding specificity for human ouabain' [patent_app_type] => 1 [patent_app_number] => 8/081693 [patent_app_country] => US [patent_app_date] => 1993-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15779 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/844/05844091.pdf [firstpage_image] =>[orig_patent_app_number] => 081693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4018498 [patent_doc_number] => 05906936 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-05-25 [patent_title] => 'Endowing lymphocytes with antibody specificity' [patent_app_type] => 1 [patent_app_number] => 8/055396 [patent_app_country] => US [patent_app_date] => 1993-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 14 [patent_no_of_words] => 6684 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/906/05906936.pdf [firstpage_image] =>[orig_patent_app_number] => 055396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3992741 [patent_doc_number] => 05985656 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-11-16 [patent_title] => 'Suppressor and progenitor cells' [patent_app_type] => 1 [patent_app_number] => 7/971723 [patent_app_country] => US [patent_app_date] => 1992-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 13 [patent_no_of_words] => 18783 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/985/05985656.pdf [firstpage_image] =>[orig_patent_app_number] => 971723 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4059539 [patent_doc_number] => 06007814 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-12-28 [patent_title] => 'Therapeutic uses of the hypervariable region of monoclonal antibody M195 and constructs thereof' [patent_app_type] => 1 [patent_app_number] => 7/861967 [patent_app_country] => US [patent_app_date] => 1992-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 47 [patent_no_of_words] => 39394 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/007/06007814.pdf [firstpage_image] =>[orig_patent_app_number] => 861967 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4241052 [patent_doc_number] => 06090923 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-07-18 [patent_title] => 'Murine monoclonal antibody binding TNF.alpha.' [patent_app_type] => 1 [patent_app_number] => 7/794365 [patent_app_country] => US [patent_app_date] => 1991-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 3317 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/090/06090923.pdf [firstpage_image] =>[orig_patent_app_number] => 794365 [rel_patent_id] =>[rel_patent_doc_number] =>)